US Stock MarketDetailed Quotes
HRTX Heron Therapeutics
- 2.475
- +0.025+1.02%
Trading Apr 29 15:17 ET
372.06MMarket Cap-3093P/E (TTM)
2.550High2.450Low1.33MVolume2.450Open2.450Pre Close3.32MTurnover1.09%Turnover RatioLossP/E (Static)150.33MShares3.22052wk High-10.95P/B301.76MFloat Cap0.50052wk Low--Dividend TTM121.92MShs Float830.000Historical High--Div YieldTTM4.08%Amplitude0.500Historical Low2.502Avg Price1Lot Size
Heron Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 59.98%-58.79M | 106.54%2.46M | 75.24%-9.18M | 4.26%-27.17M | 43.33%-24.9M | 27.76%-146.91M | 17.07%-37.53M | 30.28%-37.07M | 54.96%-28.37M | -4.77%-43.94M |
| Net income from continuing operations | 39.26%-110.56M | 46.03%-10.72M | 40.33%-25.01M | 25.37%-42.06M | 48.71%-32.77M | 17.52%-182.02M | 63.64%-19.87M | 20.04%-41.91M | 7.63%-56.36M | -21.43%-63.89M |
| Operating gains losses | -86.49%10K | ---13K | --0 | ---- | ---- | -91.00%74K | --0 | ---22K | --0 | --96K |
| Depreciation and amortization | 0.35%2.9M | -9.61%715K | 2.97%727K | 10.13%739K | -0.42%718K | -4.37%2.89M | -0.38%791K | -6.37%706K | -8.58%671K | -2.44%721K |
| Other non cash items | 67.82%339K | 226.00%163K | 40.38%73K | 4.00%52K | 2.00%51K | -77.65%202K | 0.00%50K | -24.64%52K | -82.33%50K | -90.04%50K |
| Change In working capital | 259.81%16.79M | 129.45%8.4M | 224.00%8.53M | -97.71%386K | -106.59%-528K | 70.05%-10.51M | -428.34%-28.53M | 47.19%-6.88M | 216.63%16.88M | 467.88%8.02M |
| -Change in receivables | 51.13%-8.09M | 137.10%3.66M | 784.24%12.9M | -3,255.63%-25.25M | 110.72%601K | -360.59%-16.55M | -229.97%-9.86M | -300.21%-1.89M | 119.56%800K | -268.54%-5.6M |
| -Change in inventory | 301.31%12.46M | 95.59%-103K | -71.19%2.62M | 253.38%7.44M | 131.08%2.51M | 4.42%-6.19M | 66.08%-2.33M | 599.46%9.08M | -2,735.09%-4.85M | -1,017.13%-8.09M |
| -Change in prepaid assets | 1,427.33%15.43M | 203.58%4.89M | -89.43%172K | 110.15%9.46M | 323.70%906K | 112.04%1.01M | -75.19%-4.72M | 141.63%1.63M | 381.60%4.5M | 85.10%-405K |
| -Change in payables and accrued expense | -126.82%-3.01M | 99.67%-38K | 54.42%-7.16M | -46.84%8.73M | -120.57%-4.55M | 142.25%11.23M | -240.19%-11.61M | -57.93%-15.7M | 247.34%16.43M | 1,172.41%22.11M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 59.98%-58.79M | 106.54%2.46M | 75.24%-9.18M | 4.26%-27.17M | 43.33%-24.9M | 27.76%-146.91M | 17.07%-37.53M | 30.28%-37.07M | 54.96%-28.37M | -4.77%-43.94M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 641.37%18M | -537.21%-8.84M | 35.58%-23.22M | -33.09%13.22M | 236.51%36.83M | -110.16%-3.32M | 108.33%2.02M | -266.62%-36.05M | -50.23%19.76M | 351.98%10.95M |
| Net PPE purchase and sale | 4.13%-1.53M | 42.34%-237K | -744.72%-793K | 13.66%-278K | 77.33%-224K | 46.56%-1.6M | -14.80%-411K | 108.03%123K | -2.22%-322K | -25.70%-988K |
| Net investment purchase and sale | 1,231.34%19.53M | -453.58%-8.6M | 37.99%-22.43M | -32.78%13.5M | 210.52%37.06M | -104.83%-1.73M | 110.18%2.43M | -256.14%-36.17M | -49.82%20.08M | 435.41%11.93M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 641.37%18M | -537.21%-8.84M | 35.58%-23.22M | -33.09%13.22M | 236.51%36.83M | -110.16%-3.32M | 108.33%2.02M | -266.62%-36.05M | -50.23%19.76M | 351.98%10.95M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -27.91%54.11M | -54.67%199K | -28.22%53.8M | 1.27%319K | 67.35%-208K | -51.89%75.06M | -9.86%439K | 105,652.11%74.94M | -99.80%315K | -172.14%-637K |
| Net issuance payments of debt | --24.35M | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net common stock issuance | -60.40%29.76M | --0 | ---- | ---- | ---- | --75.15M | ---18K | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | 102.33%2K | -56.46%199K | -39.37%-308K | 1.27%319K | 67.35%-208K | -101.22%-86K | -6.16%457K | -325.00%-221K | -94.52%315K | -172.14%-637K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -27.91%54.11M | -54.67%199K | -28.22%53.8M | 1.27%319K | 67.35%-208K | -51.89%75.06M | -9.86%439K | 105,652.11%74.94M | -99.80%315K | -172.14%-637K |
| Net cash flow | ||||||||||
| Beginning cash position | -83.03%15.36M | -30.89%34.86M | -72.31%13.46M | -52.40%27.09M | -83.03%15.36M | -13.88%90.54M | -68.39%50.44M | -74.57%48.61M | -4.73%56.91M | -13.88%90.54M |
| Current changes in cash | 117.71%13.31M | 82.37%-6.18M | 1,069.87%21.4M | -64.15%-13.63M | 134.87%11.73M | -415.02%-75.18M | 49.19%-35.07M | 105.79%1.83M | -106.32%-8.3M | 25.92%-33.63M |
| End cash Position | 86.65%28.68M | 86.65%28.68M | -30.89%34.86M | -72.31%13.46M | -52.40%27.09M | -83.03%15.36M | -83.03%15.36M | -68.39%50.44M | -74.57%48.61M | -4.73%56.91M |
| Free cash flow | 59.44%-60.33M | 105.81%2.21M | 73.13%-9.97M | 4.36%-27.44M | 44.15%-25.12M | 27.93%-148.74M | 16.87%-37.95M | 32.15%-37.11M | 54.67%-28.7M | -5.29%-44.98M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg